(SNN) Smith & Nephew SNATS - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NYSE (USA) | Market Cap: 13.717m USD | Total Return: 26.6% in 12m

Implants, Repair, Wound Care, Surgical Tools
Total Rating 64
Safety 87
Buy Signal 0.07
Medical Devices
Industry Rotation: -6.3
Market Cap: 13.7B
Avg Turnover: 22.2M USD
ATR: 2.09%
Peers RS (IBD): 66.9
Risk 5d forecast
Volatility27.8%
Rel. Tail Risk-10.8%
Reward TTM
Sharpe Ratio0.72
Alpha7.54
Character TTM
Beta0.223
Beta Downside0.246
Drawdowns 3y
Max DD33.29%
CAGR/Max DD0.17
EPS (Earnings per Share) EPS (Earnings per Share) of SNN over the last years for every Quarter: "2021-03": 0.1165, "2021-06": 0.78, "2021-09": 0, "2021-12": 0.36, "2022-03": 0, "2022-06": 0.2, "2022-09": 0, "2022-12": 0.05, "2023-03": 0, "2023-06": 0.35, "2023-09": 0, "2023-12": 1.31, "2024-03": 0, "2024-06": 0.756, "2024-09": 0, "2024-12": 0.23, "2025-03": 0, "2025-06": 0.33, "2025-09": 0, "2025-12": 0.38, "2026-03": 0,
EPS CAGR: -69.02%
EPS Trend: 0.9%
Last SUE: 0.00
Qual. Beats: 0
Revenue Revenue of SNN over the last years for every Quarter: 2021-03: 1299.5, 2021-06: 2599, 2021-09: 1306.5, 2021-12: 2613, 2022-03: 1300, 2022-06: 2600, 2022-09: 1307.5, 2022-12: 2615, 2023-03: 1367, 2023-06: 2734, 2023-09: 1407.5, 2023-12: 2815, 2024-03: 1413.5, 2024-06: 2827, 2024-09: null, 2024-12: 2983, 2025-03: null, 2025-06: 2987.725, 2025-09: null, 2025-12: 3190.67947, 2026-03: null,
Rev. CAGR: 5.62%
Rev. Trend: 38.9%
Qual. Beats: 0

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: SNN Smith & Nephew SNATS

Smith & Nephew plc (SNN) develops and sells medical devices globally, with operations in the United Kingdom and United States.

The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. This structure reflects the diversified nature of the medical device industry.

SNNs product offerings include knee and hip implants, trauma and extremities products, and other reconstruction solutions. The orthopedic sector is a significant part of the medical device market due to an aging global population.

The Sports Medicine & ENT segment provides minimally invasive surgery tools, soft tissue injury treatments, and arthroscopic enabling technologies. Minimally invasive procedures are a growing trend in healthcare.

The Advanced Wound Management segment focuses on acute and chronic wound care, including bioactives and negative pressure wound therapy. Wound care is an essential component of post-operative recovery and chronic disease management.

SNN serves healthcare providers and was founded in 1856, headquartered in Watford, UK. Further research on ValueRay can provide more detailed financial and operational insights.

Headlines to Watch Out For
  • Orthopaedics segment revenue growth drives overall company performance
  • Sports Medicine & ENT product innovation expands market share
  • Advanced Wound Management sales contribute to diversified revenue
  • Regulatory approvals for new medical devices impact market entry
  • Healthcare spending trends influence demand for elective procedures
Piotroski VR‑10 (Strict) 9.0
Net Income: 1.04b TTM > 0 and > 6% of Revenue
FCF/TA: 0.14 > 0.02 and ΔFCF/TA 10.56 > 1.0
NWC/Revenue: 20.92% < 20% (prev 32.03%; Δ -11.11% < -1%)
CFO/TA 0.22 > 3% & CFO 2.28b > Net Income 1.04b
Net Debt (2.77b) to EBITDA (2.82b): 0.98 < 3
Current Ratio: 2.57 > 1.5 & < 3
Outstanding Shares: last quarter (436.5m) vs 12m ago -50.03% < -2%
Gross Margin: 68.80% > 18% (prev 0.70%; Δ 6.81k% > 0.5%)
Asset Turnover: 114.2% > 50% (prev 79.40%; Δ 34.78% > 0%)
Interest Coverage Ratio: 5.05 > 6 (EBITDA TTM 2.82b / Interest Expense TTM 329.4m)
Altman Z'' 5.42
A: 0.24 (Total Current Assets 4.10b - Total Current Liabilities 1.59b) / Total Assets 10.46b
B: 0.51 (Retained Earnings 5.32b / Total Assets 10.46b)
C: 0.16 (EBIT TTM 1.66b / Avg Total Assets 10.50b)
D: 1.07 (Book Value of Equity 5.52b / Total Liabilities 5.17b)
Altman-Z'' Score: 5.42 = AAA
Beneish M -3.02
DSRI: 0.74 (Receivables 1.43b/1.35b, Revenue 11.99b/8.37b)
GMI: 1.02 (GM 68.80% / 70.20%)
AQI: 1.02 (AQ_t 0.45 / AQ_t-1 0.44)
SGI: 1.43 (Revenue 11.99b / 8.37b)
TATA: -0.12 (NI 1.04b - CFO 2.28b) / TA 10.46b)
Beneish M-Score: -3.02 (Cap -4..+1) = AA
What is the price of SNN shares? As of April 08, 2026, the stock is trading at USD 31.73 with a total of 1,953,329 shares traded.
Over the past week, the price has changed by -0.16%, over one month by -5.48%, over three months by -4.42% and over the past year by +26.62%.
Is SNN a buy, sell or hold? Smith & Nephew SNATS has received a consensus analysts rating of 3.75. Therefor, it is recommend to hold SNN.
  • StrongBuy: 1
  • Buy: 1
  • Hold: 2
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the SNN price?
Analysts Target Price 36.6 15.4%
Smith & Nephew SNATS (SNN) - Fundamental Data Overview as of 04 April 2026
P/E Trailing = 22.4755
P/E Forward = 12.4533
P/S = 2.2253
P/B = 2.5755
P/EG = 0.6557
Revenue TTM = 11.99b USD
EBIT TTM = 1.66b USD
EBITDA TTM = 2.82b USD
Long Term Debt = 3.03b USD (from longTermDebt, last quarter)
Short Term Debt = 150.0m USD (from shortTermDebt, last quarter)
Debt = 3.33b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.77b USD (from netDebt column, last quarter)
Enterprise Value = 16.49b USD (13.72b + Debt 3.33b - CCE 557.0m)
Interest Coverage Ratio = 5.05 (Ebit TTM 1.66b / Interest Expense TTM 329.4m)
EV/FCF = 11.29x (Enterprise Value 16.49b / FCF TTM 1.46b)
FCF Yield = 8.86% (FCF TTM 1.46b / Enterprise Value 16.49b)
FCF Margin = 12.18% (FCF TTM 1.46b / Revenue TTM 11.99b)
Net Margin = 8.66% (Net Income TTM 1.04b / Revenue TTM 11.99b)
Gross Margin = 68.80% ((Revenue TTM 11.99b - Cost of Revenue TTM 3.74b) / Revenue TTM)
Gross Margin QoQ = 65.56% (prev 70.62%)
Tobins Q-Ratio = 1.58 (Enterprise Value 16.49b / Total Assets 10.46b)
Interest Expense / Debt = 2.24% (Interest Expense 74.6m / Debt 3.33b)
Taxrate = 20.39% (84.7m / 415.6m)
NOPAT = 1.32b (EBIT 1.66b * (1 - 20.39%))
Current Ratio = 2.57 (Total Current Assets 4.10b / Total Current Liabilities 1.59b)
Debt / Equity = 0.63 (Debt 3.33b / totalStockholderEquity, last quarter 5.29b)
Debt / EBITDA = 0.98 (Net Debt 2.77b / EBITDA 2.82b)
Debt / FCF = 1.90 (Net Debt 2.77b / FCF TTM 1.46b)
Total Stockholder Equity = 5.32b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.89% (Net Income 1.04b / Total Assets 10.46b)
RoE = 19.51% (Net Income TTM 1.04b / Total Stockholder Equity 5.32b)
RoCE = 19.91% (EBIT 1.66b / Capital Employed (Equity 5.32b + L.T.Debt 3.03b))
RoIC = 15.46% (NOPAT 1.32b / Invested Capital 8.56b)
WACC = 5.80% (E(13.72b)/V(17.04b) * Re(6.77%) + D(3.33b)/V(17.04b) * Rd(2.24%) * (1-Tc(0.20)))
Discount Rate = 6.77% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: -100.0 | Cagr: -29.29%
[DCF] Terminal Value 88.44% ; FCFF base≈1.02b ; Y1≈1.26b ; Y5≈2.15b
[DCF] Fair Price = 139.4 (EV 62.24b - Net Debt 2.77b = Equity 59.47b / Shares 426.8m; r=6.0% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 0.90 | EPS CAGR: -69.02% | SUE: 0.0 | # QB: 0
Revenue Correlation: 38.94 | Revenue CAGR: 5.62% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=2.05 | Chg7d=+0.237 | Chg30d=+0.242 | Revisions Net=+0 | Growth EPS=+0.5% | Growth Revenue=+6.5%
EPS next Year (2027-12-31): EPS=2.09 | Chg7d=+0.287 | Chg30d=+0.287 | Revisions Net=+1 | Growth EPS=+2.0% | Growth Revenue=+5.6%
[Analyst] Revisions Ratio: +0.00 (1 Up / 1 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 3.5% (Discount Rate 7.9% - Earnings Yield 4.4%)
[Growth] Growth Spread = +2.2% (Analyst 5.6% - Implied 3.5%)
External Resources
Dataroma Stockcircle